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Abstract
Background: The place where a patient experiences his/her first panic attack (FPA) may be related to their
agoraphobia later in life. However, no investigations have been done into the clinical features according to the
place where the FPA was experienced. In particular, there is an absence of detailed research examining patients
who experienced their FPA at home. In this study, patients were classified by the location of their FPA and the
differences in their clinical features were explored (e.g., symptoms of FPA, frequency of agoraphobia, and severity
of FPA).
Methods: The subjects comprised 830 panic disorder patients who were classified into 5 groups based on the
place of their FPA (home, school/office, driving a car, in a public transportation vehicle, outside of home), The
clinical features of these patients were investigated. Additionally, for panic disorder patients with agoraphobia at
their initial clinic visit, the clinical features of patients who experienced their FPA at home were compared to those
who experienced their attack elsewhere.
Results: In comparison of the FPAs of the 5 groups, significant differences were seen among the 7 descriptors (sex
ratio, drinking status, smoking status, severity of the panic attack, depression score, ratio of agoraphobia, and
degree of avoidance behavior) and 4 symptoms (sweating, chest pain, feeling dizzy, and fear of dying). The driving
and public transportation group patients showed a higher incidence of co-morbid agoraphobia than did the other
groups. Additionally, for panic disorder patients with co-morbid agoraphobia, the at-home group had a higher
frequency of fear of dying compared to the patients in the outside-of-home group and felt more severe distress
elicited by their FPA.
Conclusion: The results of this study suggest that the clinical features of panic disorder patients vary according to
the place of their FPA. The at-home group patients experienced “fear of dying” more frequently and felt more
distress during their FPA than did the subjects in the other groups. These results indicate that patients
experiencing their FPA at home should be treated with a focus on the fear and distress elicited by the attack.
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Background
In recent years, panic disorder (PD) has been recognized
as a chronic disease where patients show little sponta-
neous improvement and disease progression is not
necessarily uniform [1-7]. Agoraphobia (AG) is an
anxiety symptom involving the fear of being in places or
situations from which escape might be difficult (or
embarrassing) or in which help may not be available in
the event of an unexpected or situationally predisposed
panic attack (PA) or panic-like symptoms. Agoraphobic
fears typically involve characteristic clusters of situations
that include being alone outside the home; being in a
crowd or standing in a line; being on a bridge; and tra-
veling in a bus, train, or automobile.
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linkage, a concept upheld by current biological and psy-
chological models of PD and AG [8,9]. Early predictors
for the development of AG would be important for clin-
ical practice [10] because co-morbid AG results in poor
outcomes and/or more severe PD [7,11-13]. The earliest
possible predictors of the development of AG by PD
patients are the features of the first panic attack (FPA)
[10]. One of the key features of a patient’s FPA is the
location or situation in which the individual experienced
their FPA.
The relationship between the situation in which the
FPA occurred and the subsequent development of AG
remains controversial. Some previous studies have
revealed that people who experienced their FPA in pub-
lic spaces [14] or phobogenic situations [15] have a high
tendency to be diagnosed as having PD with AG. Shul-
man et al. [16] reported that extensive avoiders were
more likely to have experienced their FPA in classic
agoraphobic situations, such as while driving or taking
public transportation. Additionally, Amering et al. [10]
reported that a public occurrence of the FPA, and the
accompanying feeling of embarrassment, was signifi-
cantly associated with the development of AG.
On the other hand, comparisons between groups of
PD patients with minimal, moderate, and marked avoid-
ance did not demonstrate differences related to the loca-
tion of the FPA or to the patients’ beliefs as to what was
happening to them [17]. Craske et al. [18] have reported
that the various places where FPAs occurred are distrib-
uted equally between minimal and extensive avoiders.
Furthermore, some of the patients who experienced
their FPA at home also developed AG. According to
previous studies, the percentages of PD patients, with
AG, who reported FPAs at home were 8% [14], 10.3%
[15], and 17% [10]. In a study comparing minimal and
extensive avoiders, the percentages of extensive avoiders,
who experienced their FPAs at home were 2.6% [16]
and 29.4% [18], respectively.
These reports suggest an association between the
location of the FPA and subsequent avoidance beha-
viors. However, the results remain inconclusive and
investigations into other clinical factors, such as demo-
graphy and symptoms experienced during the FPA,
have not been conducted. For this reason, in this
study, we classified the location of the FPA and
explored the differences in clinical features (e.g., symp-
toms of the FPA, frequency of AG, and severity of the
FPA) of five groups. Additionally, the clinical features
of patients who developed AG after experiencing their
FPA at home were examined. There was an absence of
detailed research examining patients who experienced
their FPA at home; therefore, for PD patients with AG,
the clinical features of these patients were also com-
pared to those of the patients who experienced their
FPA elsewhere.
Methods
Subjects
The study subjects consisted of 1,075 outpatients with
PD, with or without AG, who initially visited the Nagoya
Mental Clinic in Nagoya, Japan, between April 1998 and
September 2001 and who were diagnosed according to
the criteria in the Diagnostic and Statistical Manual of
Mental Disorders, 4th ed. (DSM-IV) [19]. Exclusion cri-
teria included somatic illnesses; a co-morbidity of psy-
chiatric disorders, except major depressive disorder; and
current substance-related disorders. Of the total popula-
tion, 53 patients were excluded from analysis due to a
co-morbid mental disease. Thus, we analyzed the data
of 1,022 patients.
This study was approved by the institutional ethical
committees of the Mie University School of Medicine
and the Warakukai Nagoya Mental Clinic. All subjects
who participated in this study provided written,
informed consent for study participation.
Initial visit interview and assessment
FPA symptoms and location of occurrence were docu-
mented by means of a questionnaire administered dur-
ing each patient’s initial clinic visit. The questionnaire
explained the definition of PA and described the 13
symptoms of PAs. The patients chose the symptoms
that they experienced during their FPA and filled in the
date and location of the FPA. In addition, patients
answered questions regarding their age at the time of
their FPA, the number of hospitals they had visited, and
the length of time from the FPA to the time of consulta-
tion. The onset of PD was defined as the day on which
the patient experienced his or her FPA. The patients
also scored the severity of their PD (based on the sever-
ity of their FPA, where 0 = none, 1 = mild, 2 = moder-
ate, 3 = severe, 4 = very severe); their frequency of
anticipatory anxiety (0 = never, 1 = seldom, 2 = some-
times, 3 = often, 4 = always); and their degree of avoid-
ance behaviors (0 = never, 1 = seldom, 2 = sometimes, 3
= often, 4 = always).
The Zung Self-Rating Depression Scale (SDS) is a
short, 20 items, self-administered survey that quantifies
the depression status of a patient [20,21]. The scale
yields an overall score of 20-80, with higher scores
reflecting more severe symptoms of depression.
Other demographic information was also obtained
during the initial assessment, including age, gender,
years of education, drinking status, smoking status,
family history, and duration of illness.
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First, the locations of the FPAs were classified. Some
patients (n = 192) gave incomplete responses regarding
the place of their FPA; therefore, the responses of 830
people were included in the comparison analyses. The
prevalence of AG in each group was investigated as was
the relationship between the clinical symptoms experi-
enced and the location of the FPA.
The relationship between the clinical features of the
symptoms experienced and the place of the FPA was
investigated by use of nonparametric 2 × 5 Chi-square
tests of significance for categorical data (gender, PA
symptoms, co-morbidity of AG, drinking status, smok-
ing status, family history). An analysis of variance
(ANOVA) was used to compare patient age, years of
education, age at FPA, severity of FPA, degree of
anticipation, degree of avoidance behavior, number of
hospital consultations, duration of consultations, SDS
score, and number of DSM symptoms. All statistical
inferences were made at the 5% level of p values as
significant.
In PD patients with AG, clinical features were com-
pared between the subjects who experienced their FPA
at home (n = 115) and those who experienced their
FPA outside of home (n = 267). Statistical differences
between the 2 groups (at home and outside of home)
were assessed using Chi-square tests for categorical vari-
ables, and they were also compared relative to age, years
of education, age at FPA, severity of FPA, degree of
anticipation, degree of avoidance behavior, number of
hospital consultations, duration of consultations, SDS
score, and number of DSM symptoms by using indepen-
dent sample t-tests (two-tailed). The Statistical Package
for Social Sciences (SPSS 11.5) was used for all statisti-
cal analyses.
Results
FPA location frequency and demographics
Table 1 shows the frequency of FPAs at various places.
The subjects (n = 830) were divided into 5 groups based
on the place where they experienced their FPA: at
home; at school/office; while driving a car; as a passen-
ger in a public transit vehicle (automobile, train, bus,
airplane); and outside of home (store, hospital, beauty
salon, movie theater, on the street). The most prevalent
locations where subjects experienced their FPA were at
home (37%), followed by outside of home (20%) and at
school/office (15%).
Table 1 also presents the socio-demographic data of
the subjects in the 5 groups. There were significant dif-
ferences in the gender ratio (p < 0.001), drinking status
(p = 0.002), and smoking status (p = 0.006), among the
5 groups of patients at their initial clinic visit.
FPA symptom profiles among the 5 groups
Table 2 shows the FPA symptom profiles among the
patients in the 5 groups. Of the 13 FPA symptoms,
sweating (p = 0.005), chest pain (p = 0.010), feeling
dizzy (p = 0.017), and fear of dying (p < 0.001) were
those most frequently experienced by the individuals in
the public transit group, school/office group, driving
group, and at-home group, respectively. Additionally,
the at-home group experienced more severe distress
caused by their FPA, while the office group experienced
the least severe distress.
FPA location and ratio of co-morbidity with AG at each
FPA location
The groups of individuals who experienced their FPA
while in a public transit vehicle (60.9%) or while driving
(56.0%) had significantly higher ratios of co-morbid AG
than did other groups (Table 1). In each diagnostic
group, the PD patients with AG tended to experience
their FPA while driving or in a public transit vehicle,
while the PD patients without AG tend to experience
their FPA at home (Table 1). With respect to subjective
depressive symptoms, as assessed by the SDS, indivi-
duals in the school/office group and the outside-of-
home group showed the highest scores, whereas the
driving group and the public transit group showed the
lowest scores (p = 0.033, Table 1). The degree of avoid-
ance behavior reported by patients at their initial visit
was least for the patients in the at-home group (p =
0.003, Table 1).
Clinical characteristic differences between the at-home
and outside-the-home patients with AG
T a b l e s3a n d4s h o wt h es o c i o-demographic data and
symptom profiles of the FPAs of the PD patients
included in the at home and outside-of-home groups
who also had co-morbid AG. The at-home group, com-
pared to the outside-of-home group, had a higher pro-
portion of women (p = 0.022) and experienced more
severe distress elicited by their FPA (p = 0.010). Further-
more, of the 13 FPA symptoms, the at-home group sub-
jects reported a higher frequency of fear of dying
compared to those in the outside-of-home group (OR =
0.37 (0.23-0.59), p < 0.001).
Examination of gender difference
Male-to-female ratios differed in the profiles of the 5
groups. Therefore, gender differences, not location of
the FPA, could possibly explain our results. To evaluate
this possibility, an analysis of the 5 groups was con-
ducted to assess gender differences with regard to the
symptoms of the FPA, the severity of the FPA, the ratio
of co-morbid AG, SDS scores, avoidance scores, and 4
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dizzy, and fear of dying).
Three factors showed significant differences in the
male-to-female ratio: co-morbidity of AG (M: 39.3% < F:
49.8%, p = 0.004), chest pain (M: 33% > F: 26%, p =
0.038), and fear of dying (M: 59.3% > F: 52.1%, p =
0.050). For these 3 factors, we performed the compari-
son among 5 groups based on the places each gender
experienced FPA. With regard to the co-morbidity of
AG, a significant difference was observed among males
(p = 0.003) and females (p = 0.001); for chest pain, a
significant difference was observed only among males (p
= 0.027); for fear of dying, there was a significant differ-
ence only among females (p < 0.001) who experienced
this symptom within the at-home group. However, the
tendency of each gender was almost the same as the
total sample, as shown in Table 1.
Discussion
The purpose of this study was to explore the clinical
features of FPAs, based on their location of occurrence.
This was accomplished by making comparisons among
5 groups of patients, classified by the place of their
FPAs. These comparisons revealed differences among 7
descriptors (sex ratio, drinking status, smoking status,
FPA symptom severity, SDS score, frequency of co-mor-
bid AG, and degree of avoidance behavior) and 4 symp-
toms (sweating, chest pain, feeling dizzy, and fear of
dying) associated with the FPA.
People who experienced their FPA in a public transit
vehicle or while driving demonstrated a higher fre-
quency of co-morbid AG and the highest degree of
avoidance behavior; these results are in keeping with
those of previous studies [10,14-16,18]. The present
study also confirmed that the place of the FPA
Table 1 Demographics and panic characteristics (N = 830)
Place of first PA Total (N =
830) 100%
1 At home (N
= 308)
37.10%
2 office, school
(N = 128)
15.40%
3 driving (N
= 100)
12.00%
4 train, bus (N
= 128) 15.40%
5 out of home
(N = 166)
20.00%
statistical
value (F or
chi-square)
p-
value
Age 34.60 ±
10.01
35.42 ± 10.76 33.77 ± 10.76 33.70 ± 8.18 34.27 ± 9.48 34.54 ± 9.32 0.974 0.421
Sex (M/F) 300 · 530
(36.1% ·
63.9%)
88 · 220(28.6%
· 71.4%)
61 · 67(47.7% ·
52.3%)
49 · 51(49.0%
· 51.0%)
45 · 83(35.2% ·
64.8%)
57 · 109(34.3% ·
65.7%)
22.452 <
0.001
Years of Education 13.13 ±
2.20
13.06 ± 2.15 13.06 ± 2.49 13.32 ± 2.10 13.45 ± 2.07 12.95 ± 2.20 1.245 0.29
Drinking (No/Yes) 508 · 288
(63.8% ·
36.2%)
203 · 88(69.8%
· 30.2%)
72 · 54(57.1% ·
42.9%)
52 · 43(54.7%
· 45.3%)
70 · 55(56.0% ·
44.0%)
111 · 48(69.8% ·
30.2%)
16.06 0.003
Smoking (No/Yes) 457 · 283
(61.8% ·
38.2%)
176 · 91(65.9%
· 34.1%)
73 · 42(63.5% ·
36.5%)
38 · 48(44.2%
· 55.8%)
70 · 48(59.3% ·
40.7%)
100 · 54(64.9% ·
35.1%)
14.298 0.006
Family history 531 · 284
(65.2% ·
34.8%)
192 · 112
(63.2% · 36.8%)
85 · 43(66.4% ·
33.6%)
66 · 30(68.8%
· 31.3%)
86 · 42(67.2% ·
32.8%)
102 · 57(64.2% ·
35.8%)
1.472 0.823
First Panic Attack
Age at first PA 28.96 ±
9.75
29.99 ± 10.25 27.77 ± 11.28 29.29 ± 7.87 27.84 ± 7.84 28.66 ± 9.79 1.823 0.122
Severity (0-4) 3.12 ± 0.92 3.22 ± 0.80 2.84 ± 1.03 3.20 ± 0.88 3.01 ± 1.00 3.17 ± 0.94 3.757 0.005
Consultation behavior
Consultation hospitals (n) 2.51 ± 2.08 2.59 ± 1.81 2.46 ± 1.81 2.40 ± 3.24 2.16 ± 1.60 2.72 ± 2.18 1.517 0.195
Duration of consultation
to psychiatric service
(days)
2105.48 ±
2558.39
2015.35 ±
2573.48
2300.57 ±
2746.20
1648.10 ±
1812.51
2377.37 ±
2600.39
2187.63 ±
2710.60
1.488 0.204
At the initial visit
Agoraphobia (% of each
group)
382(46.0%) 115(37.3%) 52(40.6%) 56(56.0%) 78(60.9%) 81(48.8%) 26.836 <
0.001
Depression (SDS score) 40.69 ±
12.04
40.65 ± 11.66 42.71 ± 12.21 38.66 ± 12.49 38.59 ± 12.33 42.11 ± 11.82 2.596 0.035
Anticipation anxiety (0-4) 3.08 ± 1.10 3.00 ± 1.15 3.01 ± 1.08 3.00 ± 1.10 3.14 ± 1.06 3.28 ± 1.00 .651 0.16
Avoidance (0-4) 2.30 ± 1.45 2.04 ± 1.46 2.34 ± 1.46 2.54 ± 1.41 2.46 ± 1.50 2.48 ± 1.38 4.077 0.003
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Place of first PA Total 1 At
home
2 office,
school
3 driving 4 train,
bus
5. outside of
home
statistical
value
p-value (place of 5
group)
(N =
830)
(N = 308) (N = 128) (N =
100)
(N = 128) (N = 166) F or chi-
square
First PA symptom (DSM-IV), N(%)
I Palpitations 745 (89.8) 273 (88.6) 117 (91.4) 89 (89.0) 116 (90.6) 150 (90.4) 1.033 0.905
II Sweating 420 (50.7) 134 (43.6) 69 (53.9) 59 (59.0) 78 (60.9) 80 (48.5) 15.081 0.005
III Trembling 426 (51.3) 167 (54.2) 63 (49.2) 58 (58.0) 56 (43.8) 82 (49.4) 6.231 0.183
IV Smothering 597 (71.9) 229 (74.4) 88 (68.8) 72 (72.0) 85 (66.4) 123 (74.1) 3.855 0.426
V Feeling of
choking
402 (48.4) 157 (51.0) 53 (41.4) 49 (49.0) 60 (46.9) 83 (50.0) 3.627 0.459
VI Chest pain 237 (28.6) 98 (31.8) 45 (35.2) 21 (21.0) 24 (18.8) 49 (29.5) 13.247 0.01
VII Nausea 273 (32.9) 95 (30.8) 43 (33.6) 37 (37.0) 51 (39.8) 47 (28.3) 5.757 0.218
VIII Feeling dizzy 431 (51.9) 143 (46.4) 71 (55.5) 60 (60.0) 59 (46.1) 98 (59.0) 12.09 0.017
IX Derealization 250 (30.1) 92 (29.9) 43 (33.6) 33 (33.0) 35 (27.3) 47 (28.3) 1.863 0.761
X Going crazy 428 (51.7) 170 (55.4) 55 (43.0) 59 (59.0) 65 (50.8) 79 (47.9) 8.71 0.069
XI Fear of dying 454 (54.7) 195 (63.3) 51 (39.8) 56 (56.0) 62 (48.4) 90 (54.2) 22.729 < 0.001
XII Paresthesia 248 (29.9) 105 (34.1) 34 (26.6) 29 (29.0) 36 (28.1) 44 (26.5) 4.406 0.354
XIII Chills or hot
flushes
247 (29.8) 101 (32.8) 33 (25.8) 23 (23.0) 37 (28.9) 53 (31.9) 4.928 0.295
Total number (1-13) 6.21 ±
2.82
6.33 ±
2.78
5.99 ± 2.87 6.50 ±
2.67
5.97 ±
3.05
6.19 ± 2.77 0.826 0.509
Table 3 Demographics and panic characteristics (N = 382, mean ± SD)
Place of first PA at home outside of home statistical
value
p-
value
OR 95%
Confidence
Interval
(N = 115) (N = 267) F or chi-square Lower Upper
Age 35.37 ± 10.03 33.95 ± 8.79 3.86 0.189
Sex (M/F) 26/89 (22.6%/77.4%) 92/175 (34.5%/
65.5%)
5.29 0.022 0.556 0.335 0.920
Years of Educatiion 13.0 ± 2.16 13.21 ± 2.29 1.24 0.431
Drinking (No/Yes) 72/34 (67.9%/32.1%) 164/94 (63.6%/
36.4%)
0.63 0.470 1.214 0.751 1.962
Smoking (No/Yes) 67/38 (63.8%//
36.2%)
149/98 (60.3%/
39.7%)
0.38 0.552 1.160 0.723 1.860
Family history (No/Yes) 78/36 (68.4%/31.6%) 177/82 (68.3%/
31.7%)
0.00 1.000 1.004 0.625 1.612
First Panic Attack
Age at first PA 28.39 ± 9.14 27.40 ± 7.96 2.05 0.286
Severity (0-4) 3.31 ± 0.74 3.06 ± 0.98 6.03 0.010
Total number (1-13) of FPA symptons 6.64 ± 2.53 6.12 ± 2.80 3.56 0.083
Consultation behavior
Consultation hospitals (n) 2.91 ± 2.11 2.54 ± 2.12 0.33 0.116
Duration of consultation to psychiatric service
(days)
2552.15 ± 2748.88 2474.13 ± 2641.34 1.05 0.794
At the initial visit
Depression (SDS score) 41.24 ± 10.98 40.63 ± 11.89 0.22 0.669
Anticipation anxiety (0-4) 3.23 ± 1.08 3.32 ± 0.92 3.38 0.445
Avoidance (0-4) 2.90 ± 1.08 2.83 ± 1.30 8.80 0.592
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diagnosed with PD and co-morbid AG, those who
experienced their FPA at home more frequently experi-
enced a fear of dying during their FPA and felt more
distress than those in the group that experienced their
FPA outside the home. Thus, the patients in these 2
groups are considered to have different clinical features.
At-home group
A smaller proportion of people who experience their
FPA at home subsequently developed AG. However, a
significant proportion of individuals within this group
(37%) still developed AG. The results show a similar fre-
quency as has been reported in previous studies
[10,14-16,18].
In this study, patients in the at-home group experi-
enced a fear of dying more frequently than did patients
in any other group. This finding suggests that fear of
dying might be a characteristic symptom of people who
experience their FPA at home. Vickers and McNally
(2005) [22] reported that the fear of dying is the symp-
tom that best distinguishes the panic attacks of indivi-
duals diagnosed with PD from those without PD. In
their study, the fear of dying had the largest effect size,
an association with PD that persisted after control for
other symptoms, and a continued importance after mul-
tivariate analyses. Additionally, Segui et al. [23] reported
that palpitations (86.7%), shortness of breath (76.5%),
fear of dying (69.9%), and dizziness (63.6%) were the
most frequent and intense symptoms reported by PD
patients. Cox et al. [24] also reported that, of the DSM
symptoms, fear of dying and tachycardia were the symp-
toms most often rated as very severe. The findings in
the current study suggest that patients experiencing the
most severe symptoms during their FPA were those
who experienced that attack at home. The fact that the
at-home group of patients experienced more severe
symptoms during their FPA than did those in other
groups, suggests that early interventional treatment of
PD may be particularly important to the patients in the
at-home group.
FPA symptoms and the location of the FPA
Other than fear of dying, significant differences were
found for 3 other symptoms and were related to the
location of the FPA. A higher proportion of patients in
the driving and public transit groups experienced sweat-
ing. In clinical practice, many PA patients describe this
symptom, including descriptions of experiences such as
wet hands while driving. Some s t u d i e sr e p o r tt h a ts u c h
autonomic occurrences may be a symptom subtype that
is often mixed into other groups of physical symptoms.
Chest pain was a physical symptom experienced by a
higher proportion of the patients who had their FPA
while at school/office as well as by those in the at-home
group. Lang et al. [25] reported that chest pain or dis-
comfort occurred more often in cases of PD without
AG. The school/office group and the at-home group
had the lowest rate of AG, suggesting that the current
results are consistent with those of the Lang et al. [25]
report.
Feeling dizzy was reported by a higher proportion of
the patients classified into the driving and outside home
groups. Several studies have reported a relationship
between feeling dizzy and AG. Yardley et al. [26] studied
the prevalence of PD symptoms in a sample of patients
Table 4 At home group vs outside of home group in PD with AG (N = 382)
Item Odds Ratio (95%CI) _2 p-value Experience rate
At home (N = 115) Outside of home
I Palpitations 1.78 (0.79-4.00) 1.974 0.19 0.90 0.94
II Sweating 1.11 (0.72-1.72) 0.218 0.66 0.53 0.56
III Trembling 0.87 (0.56-1.36) 0.361 0.58 0.54 0.51
IV Smothering 0.68 (0.40-1.15) 2.088 0.16 0.80 0.73
V Feeling of choking 0.88 (0.57-1.37) 0.311 0.66 0.52 0.49
VI Chest pain 0.69 (0.42-1.14) 2.129 0.15 0.28 0.21
VII Nausea 0.95 (0.60-1.51) 0.041 0.91 0.35 0.34
VIII Feeling dizzy 1.35(0.87-2.09) 1.796 0.18 0.46 0.54
IX Derealization 1.04 (0.65-1.67) 0.03 0.91 0.31 0.32
X Going crazy 0.67 (0.43-1.05) 3.068 0.09 0.61 0.51
XI Fear of dying 0.37(0.23-0.59) 18.046 < 0.001 0.70 0.47
XII Paresthesia 0.65 (0.40-1.06) 3.035 0.10 0.31 0.23
XIII Chills or hot flushes 0.82(0.51-1.32) 0.647 0.46 0.32 0.28
df = 1
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them psychosocially. Patients with panic-related dizzi-
ness were reported to have higher rates of vertigo and
agoraphobic behavior when compared to those patients
who had only panic or dizziness alone. Jacob et al. [27]
reported that vestibular symptoms during panic spells
are not necessarily related to the presence of vestibular
dysfunctions that are objectively identifiable; nonethe-
less, patients with PD associated with AG have signifi-
cantly more vestibular disorders than other patients.
Vaillancourt and Bélanger [28] also reported that people
suffering from both PD and dysfunctions of the equili-
brium system might avoid activities that rely heavily
upon good balance; such as walking on uneven surfaces
or undertaking some forms of transportation. Thus, the
driving group, as well as the outside-of-home group,
which demonstrated higher rates of AG had been active
outside of the home (e.g., walking on the street) in an
adverse situation and experienced a higher frequency of
feeling dizzy.
Other factors
Other demographic characteristics also show significant
differences when classified according to the reported
place where the patient’s FPA was experienced. The at-
home group showed a high proportion of females, while
the school/office and driving groups showed a high pro-
portion of males. As might be expected, the place where
a particular group of people spends the majority of their
daily life influences this result (for example, there are
many women who remain at home and a higher propor-
tion of men who spend significant amounts of time driv-
ing and at work).
A higher proportion of people in the school/office,
driving, and public transit groups reported alcohol con-
sumption than in other groups. Interestingly, PD occurs
at a higher rate among alcohol abusers [29,30]. Craske
et al. [18] found that the majority of their PD subjects
reported only 1 life stressor and it was often related to
ill-health or alcohol use.
A far higher proportion of subjects in the driving
group were reported to be smokers. This group was also
observed to have a higher proportion of men; therefore,
there may be a relationship between male smokers and
PD. Pohl et al. [31] reported that the prevalence of
smoking was significantly higher in female PD patients
than for control subjects (40% vs. 25%). However, smok-
ing rates among males did not differ between PD
patients and control subjects. Other studies have
reported that patients with anxiety disorders have a
greater propensity to be smokers [32,33]. These incon-
sistencies suggest that further study regarding the asso-
ciation between smoking and AG are required.
Limitations
There were several limitations to this study. First, it was
difficult to define the timing of some individuals’ FPA.
People who had experienced their FPA during childhood
had difficulty remembering the experience in detail. As a
result, there were a large number of blanks when
describing the place, situation, or symptoms of the FPA.
This led to nearly 200 responses being excluded from
the final data analysis. In contrast, because the FPA was
a high-impact event, many occurrences were described
in detail and are believed to be reliable. The finding that
a great majority of PD patients are able to vividly
describe their FPA was first described by Lelliot [14]
and confirmed in a later study [10].
Second, like all previous studies describing the onset
of PDs, the present one was necessarily retrospective.
The main problem in studying the onset of PD is the
difficulty associated with prospectively studying large
cohorts of subjects, as prodromal symptoms of anxiety
disorders are highly prevalent in the general population
[34]. With this limitation in mind, the best strategy is to
recruit patients at the first stage of illness, after the
initial consultation with emergency services or general
practitioners. This approach would allow for the oppor-
tunity to analyze patient clinical features before the start
of treatment and to follow them prospectively.
Third, a gender difference was observed with regard to
the place of the patient’s FPA, suggesting that an indivi-
dual’s daily routine influences the location of their FPA.
In this study, men and women demonstrated similar
tendencies toward symptoms within each location of the
FPA. However, further investigation into the impact of
gender differences and lifestyles on FPA symptoms are
required.
Conclusion
The purpose of this study was to determine the associa-
tion between the clinical features and location at which
an individual experiences his or her FPA and the devel-
opment of AG. The present study shows that the public
transit vehicle and driving groups have a high tendency
to demonstrate co-morbid AG. The result suggests that
the PD patients who experienced FPA in a public transit
vehicle or while driving might be monitored with parti-
cular attention to co-morbidity of AG at every visit.
Additionally, the at-home group experienced distinctly
different clinical features as compared to those whose
FPA occurred in outside-of-home locations. The at-
home group of patients experienced “fear of dying”
symptoms more frequently and felt more distress during
their FPA. The results indicate that patients experien-
cing their FPA at home should be treated with a focus
on the fear and distress elicited by their FPA. We
Hara et al. BioPsychoSocial Medicine 2012, 6:12
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Page 7 of 8conclude that PD is heterogeneous, and the further
examinations are needed in order to provide a specific
intervention to meet individual symptoms.
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